Fuentes, Mary Esmeralda
Lu, Xiaoyin
Flores, Natasha M.
Hausmann, Simone
Mazur, Pawel K.
Funding for this research was provided by:
National Institutes of Health (R01CA236118, R01CA278940, R01CA272844, R01CA236949, R01CA266280, R01CA272843, K99CA255936)
Neuroendocrine Tumor Research Foundation (NETRF-Mazur)
U.S. Department of Defense (CA181486)
Cancer Prevention and Research Institute of Texas (RP220391 and RR160078, RP210028, RP210028)
American Cancer Society (Postdoctoral Fellowship)
Article History
Received: 17 November 2023
Accepted: 3 April 2024
First Online: 12 April 2024
Competing interests
: P.K.M. is a co-scientific founder, consultant, and stockholder of Amplified Medicines, Inc.; consultant and stockholder of Ikena Oncology, Inc. and Alternative Bio, Inc. The other authors declare no competing interests.